This is a preprint.
Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
- PMID: 38712091
- PMCID: PMC11071577
- DOI: 10.1101/2024.03.13.24304161
Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
Update in
-
Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder.Nat Genet. 2025 Jun;57(6):1389-1401. doi: 10.1038/s41588-025-02189-z. Epub 2025 May 13. Nat Genet. 2025. PMID: 40360802 Free PMC article.
Abstract
Obsessive-compulsive disorder (OCD) affects ~1% of children and adults and is partly caused by genetic factors. We conducted a genome-wide association study (GWAS) meta-analysis combining 53,660 OCD cases and 2,044,417 controls and identified 30 independent genome-wide significant loci. Gene-based approaches identified 249 potential effector genes for OCD, with 25 of these classified as the most likely causal candidates, including WDR6, DALRD3, CTNND1 and multiple genes in the MHC region. We estimated that ~11,500 genetic variants explained 90% of OCD genetic heritability. OCD genetic risk was associated with excitatory neurons in the hippocampus and cortex, along with D1- and D2-type dopamine receptor-containing medium spiny neurons. OCD genetic risk was shared with 65 of 112 additional phenotypes, including all of the psychiatric disorders we examined. In particular, OCD shared genetic risk with anxiety, depression, anorexia nervosa, and Tourette syndrome, and was negatively associated with inflammatory bowel diseases, educational attainment, and body mass index.
Conflict of interest statement
Chris German is employed by and holds stock or stock options in 23andMe, Inc. Erika L. Nurmi is on the Scientific Advisory Board for Myriad Genetics and Medical Advisory Board for Tourette Association of America and received Clinical trial funding from Emalex and Octapharma Pharmaceuticals. Jeremy Veenstra-VanderWeele has served on advisory boards or consulted with Roche, Novartis, and SynapDx; received research funding from Roche, Novartis, SynapDx, Seaside Therapeutics, Forest, Janssen, Acadia, Yamo, and MapLight; received stipends for editorial work from Wiley and Springer. Jens R. Wendland is a current employee and shareholder of Takeda Pharmaceuticals and a past employee and shareholder of F. Hoffmann-La Roche, Pfizer and Nestle Health Science. Cynthia M. Bulik reports: Pearson (author, royalty recipient). Peter Falkai reports no conflict of interest regarding this study and reports to have received financial support and Advisory Board: Richter, Recordati, Boehringer-Ingelheim, Otsuka, Janssen and Lundbeck. Hans J. Grabe has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care. Ian B. Hickie is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney, Australia. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca, Janssen Cilag) projects focused on the identification and better management of anxiety and depression. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd which aims to transform mental health services through the use of innovative technologies. Benjamin M. Neale is a member of the scientific advisory board at Deep Genomics and Neumora. Christopher Pittenger consults and/or receives research support from Biohaven Pharmaceuticals, Freedom Biosciences, Ceruvia Lifesciences, Transcend Therapeutics, UCB BioPharma, and F-Prime Capital Partners. He owns equity in Alco Therapeutics. These relationships are not related to the current work. Dan J. Stein has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, L’Oreal, Lundbeck, Orion, Sanofi, Servier, Takeda and Vistagen. Eric A. Storch reports receiving research funding to his institution from the Ream Foundation, International OCD Foundation, and NIH. He was formerly a consultant for Brainsway and Biohaven Pharmaceuticals in the past 12 months. He owns stock less than $5000 in NView/Proem for distribution related to the YBOCS scales. He receives book royalties from Elsevier, Wiley, Oxford, American Psychological Association, Guildford, Springer, Routledge, and Jessica Kingsley. Ole A. Andreasson reports to be a consultant to Cortechs.ai, Precision Health AS, speakers honorarium from Otsuka, Lundbeck, Sunovion, Janssen. Anders D. Børglum has received a speaker fee from Lundbeck. David Mataix-Cols receives royalties for contributing articles to UpToDate, Wolters Kluwer Health, and personal fees for editorial work from Elsevier, all unrelated to the current work. Murray B. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, BigHealth, Biogen, Bionomics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, Otsuka, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). Joel Gelernter is paid for editorial work by the journal Complex Psychiatry. Pino Alonso has received funding from Biohaven, Boston Scientific, Medtronic. All other authors report no conflicts of interest.
Figures
References
-
- Fawcett E. J., Power H. & Fawcett J. M. Women are at greater risk of OCD than men: a meta-analytic review of OCD prevalence worldwide. J. Clin. Psychiatry 81, 19r13085 (2020). - PubMed
-
- World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: WHO Press; (2008).
Methods-only references
-
- DSM-5. Diagnostic and statistical manual of mental disorders: DSM-5. 237–242. ISBN 978–0-89042–555–8 (2013).
-
- World Health Organization. ICD-11: International classification of diseases (11th revision), https://icd.who.int/ (2019).
Publication types
Associated data
Grants and funding
- R01 MH071507/MH/NIMH NIH HHS/United States
- R01 MH101493/MH/NIMH NIH HHS/United States
- R01 DA054869/DA/NIDA NIH HHS/United States
- S10 RR025141/RR/NCRR NIH HHS/United States
- R01 MH079488/MH/NIMH NIH HHS/United States
- I01 CX001849/CX/CSRD VA/United States
- R01 MH079494/MH/NIMH NIH HHS/United States
- RC2 GM092618/GM/NIGMS NIH HHS/United States
- P50 GM115305/GM/NIGMS NIH HHS/United States
- R01 MH124871/MH/NIMH NIH HHS/United States
- R56 AG068026/AG/NIA NIH HHS/United States
- R01 MH113362/MH/NIMH NIH HHS/United States
- R56 MH120736/MH/NIMH NIH HHS/United States
- K99 MH128540/MH/NIMH NIH HHS/United States
- R01 MH124851/MH/NIMH NIH HHS/United States
- R01 MH103657/MH/NIMH NIH HHS/United States
- R01 NS102371/NS/NINDS NIH HHS/United States
- UL1 TR000445/TR/NCATS NIH HHS/United States
- R01 MH079487/MH/NIMH NIH HHS/United States
- R01 MH050214/MH/NIMH NIH HHS/United States
- IK2 BX005058/BX/BLRD VA/United States
- R01 MH124679/MH/NIMH NIH HHS/United States
- IP1 HX002375/HX/HSRD VA/United States
- T32 GM080178/GM/NIGMS NIH HHS/United States
- T32 GM008042/GM/NIGMS NIH HHS/United States
- R01 NS105746/NS/NINDS NIH HHS/United States
- U19 HL065962/HL/NHLBI NIH HHS/United States
- R21 MH109938/MH/NIMH NIH HHS/United States
- R01 MH079489/MH/NIMH NIH HHS/United States
- R01 MH085321/MH/NIMH NIH HHS/United States
- R01 MH059299/MH/NIMH NIH HHS/United States
- R01 MH124873/MH/NIMH NIH HHS/United States
- R01 MH093381/MH/NIMH NIH HHS/United States
- R01 AA026364/AA/NIAAA NIH HHS/United States
- R01 HD074711/HD/NICHD NIH HHS/United States
- R01 MH114927/MH/NIMH NIH HHS/United States
- U01 HG006378/HG/NHGRI NIH HHS/United States
- K23 MH066284/MH/NIMH NIH HHS/United States
- R01 MH058376/MH/NIMH NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- R01 MH105500/MH/NIMH NIH HHS/United States
- R01 NS032830/NS/NINDS NIH HHS/United States
- U01 HG004798/HG/NHGRI NIH HHS/United States
- U10 AA008401/AA/NIAAA NIH HHS/United States
- R01 MH110427/MH/NIMH NIH HHS/United States
- UL1 TR002243/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous